In this pandemic, the only glimmer of light at the end of the tunnel has been the question of vaccination. This is because, in the face of the disease that has so worried the population, countless companies started to dedicate themselves to the development of a candidate for the vaccine. However, on Wednesday (14), the deputy director-general of WHO (World Health Organization), Mariângela Simão, guaranteed that Brazil will not have a mass vaccination against COVID-19 in 2021.
During an interview with CNN Brasil, the deputy director-general of WHO (World Health Organization) stated: “There will not be enough vaccine next year to vaccinate the entire population, so what WHO is advising is that there should be a prioritization to vaccinate health professionals and people over 65 or who have an associated disease “.
On the occasion, Mariângela added: “I would say that 2022 is a year that we will have more vaccines because we have so much vaccine under development … It is likely that we will have other vaccines that arrive next year, proving to be safe. and effective “, and concluded:” The important thing now is not to immunize everyone in one country, which is impossible: it is to immunize those who need it in all countries “.
Vaccination in Brazil
With the vaccine race in mind, Brazil invests in direct partnerships with countries or pharmaceutical companies that develop their own vaccines, such as the Oxford and CoronaVac vaccines, in which the country invests resources to finance part of the research and, later, receive the technology for the domestic production of vaccines. This Oxford vaccine, produced by the AstraZeneca laboratory, was the first to send the first documents to be analyzed by Anvisa, and if approved, 30 million doses should arrive in Brazil in January 2021. In addition, another 70 million doses doses will be produced by the Oswaldo Cruz Foundation (Fiocruz) in the first half of next year.
The pharmaceutical company Sinovac, responsible for the CoronaVac vaccine, has also sent part of the clinical studies to be analyzed by Anvisa. In Brazil, CoronaVac’s agreement is with the state of São Paulo and coordinated by the Butantan Institute, providing for the supply of 46 million doses of the immunizer by the end of this year.
It is worth looking at the possibility of a similar partnership between Brazil and the Russian immunizer, Sptunik V. In this case, the governments of Paraná and Bahia have already established interest with the Russian authorities – however, the research has not yet started in no Brazilian state, according to Anvisa.
Source: CNN Brasil
Did you like this article?
Subscribe your email to Canaltech to receive daily updates with the latest news from the world of technology.